IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2 CHF | 0.00% |
|
-3.85% | -5.39% |
| Apr. 11 | Swiss Market Index Falls as ECB Signals June Rate Cut | MT |
| Apr. 11 | Idorsia to Revise July 2024 Convertible Bond Terms, Conditions | MT |
Presenter SpeechAndrew Weiss (Executives)Good afternoon, good morning, everyone. My name is An...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
2024-04-25
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2
CHF
Average target price
1.724
CHF
Spread / Average Target
-13.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.39% | 392M | |
| -0.49% | 103B | |
| +3.31% | 96.73B | |
| +1.66% | 21.31B | |
| -16.16% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.87% | 13.68B | |
| +6.32% | 13.44B | |
| +21.46% | 10.98B |
- Stock Market
- Equities
- IDIA Stock
- News Idorsia Ltd
- Transcript : Idorsia Ltd - Special Call
